Project Grant R01CA282501
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$641K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
The National Cancer Institute (NCI) awarded a 3-year, $183,398 Project Grant to The Ohio State University under the Cancer Research Manpower (CFDA 93.398) program. The goal of the project is to elucidate the mechanisms by which tumor hypoxia (low oxygen) contributes to immune privilege and treatment resistance in non-small cell lung cancer (NSCLC) tumors. The researchers will investigate the use of mitochondrial inhibitors, such as papaverine (PPV) and SMV-32, to reoxygenate the NSCLC tumor...
The National Cancer Institute (NCI) awarded a $234,749 Project Grant under CFDA 93.395 - Cancer Treatment Research to The Ohio State University to conduct a multi-center Phase Ib clinical trial testing the combination of the Hedgehog inhibitor Vismodegib and the anti-PD-L1 therapy Atezolizumab in patients with metastatic non-small cell lung cancer (NSCLC). The project aims to investigate the role of Hedgehog signaling in tumor-associated macrophages (TAMs) and its impact on CD8+ T cell...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
The federal Project Grant award of $281,370 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at The Ohio State University to overcome immunotherapy resistance in lung cancers with STK11 gene mutations. The key objectives are to: 1) characterize the relationship between tumor differentiation phenotypes, the tumor immune microenvironment, and response to immune checkpoint blockade, including validating a novel STK11-MLDD biomarker; and 2)...
This $670,358 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate the role of B cell lineages in mediating response to neoadjuvant immune-based therapy for resectable non-small cell lung cancer (NSCLC). The research will leverage unique clinical trial cohorts, human-relevant mouse models, and advanced multi-omics technologies to determine the transcriptional, immunogenomic, and spatial landscapes of B lineage cells in NSCLC...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $650,450 to the University of Southern California to develop a novel cancer immunotherapy using genetically engineered CD4+ T cells targeting the CT83 tumor antigen. The research aims to determine the mechanisms by which these engineered T cells eliminate lung cancer cells, produce GMP-grade master cell banks and viral particles, and develop a scalable...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Florida aims to characterize a bacterial-derived metabolite called BAC429 and its role in enhancing the efficacy of anti-PD-1 immunotherapy for non-small cell lung cancer (NSCLC). The $540,288 award, active from May 1, 2025 to April 30, 2030, will support research with the following key objectives: 1) Define the functional impact of BAC429 on experimental NSCLC, 2) Establish...
This Project Grant award of $127,629, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports a multi-omic research study on the role of human leukocyte antigen (HLA) variations in immune response and efficacy of immune checkpoint inhibitor (ICI) monotherapy for non-small cell lung cancer (NSCLC). The key products and services to be delivered under this 2-year award include: Identifying the mechanisms linking germline and somatic HLA...